Publications

5543 Results

Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): results from the Phase III SWOG S1216 trial of androgen deprivation +/- orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;M LeBlanc;I Thompson;N Agarwal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 5048); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radial Cystectomy for Muscle Invasive Urothelial Cancer

Authors
SP Lerner;C Tangen;R Svatek;S Daneshmand;K Pohar;E Skinner;A Schuckman;A Sagalowsky;N Smith;A Kamat;W Kassouf;M Plets;R Bangs;T Koppie;A Alva;F La Rosa;S Pal;A Kibel;D Canter;I Thompson
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 4508); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
S1011

A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Authors
J Del Rivero;K Perez;S Geyer;M Khalil;A Vijendran;A Kordaris-Corkill;A Shegrill;H Soares;C Lopez;A Nixon;A Dueck;J Meyerhardt;E O'Reilly
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4191); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A021804

Results of a Phase 3 study of IVO vs IO for Previously Untreated Older Patients with CLL and Impact of COVID-19

Authors
J Woyach;J Yin;J Brown;S Dinner;G Lozanski;R Little;C Miller;S Coutre;W Ding;B Hill;G Perez;A Ruppert;A Wall;D Feldman;E Dib;H Erba;R Stone;J Byrd
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 7500); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Leukemia

A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur)

Authors
K Hitchcock;P Romesser;Q Shi;J Dixon;S Gholami;S White;C Wu;C Goulet;K Jee;C Wright;R Yaeger;A Shergill;T Hong;T George;E O'Reilly;J Meyerhardt;E Miller
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3629); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A022101

A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902)

Authors
J Olson;J Allred;S Schuetze;E Davis;A Poklepovic;M Wagner;B Waechter;R Reidel;M Xu-Welliver;S Berg;S George;S Robinson;P Googe;S DAngelo;G Schwartz
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 11503); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023

A022104/NRG-GI010: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER | THE JANUS RECTAL CANCER TRIAL

Authors
JJ Smith;A Dasari;Q Shi;J Garcia-Aguilar;H Sanoff;T George;T Hong;G Yothers;P Philip;G Nelson;T Al Baghdadi;E O'Reilly;J Meyerhardt;A Shergill;N Horvat;P Romesser;W Hall
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3640); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal

Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer

Authors
A Chawla;Q Shi;A Ko;M Beg;A Varghese;M Noel;M Bloomston;F Ahmed;W Frankel;J Dixon;X Carrero;A Shergill;J Crawley;O Akin;D Renouf;G Zogopoulos;J Hubbard;J Meyerhardt;E O'Reilly;C Ferrone
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS4204); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/A021806

Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma (Alliance A092001)

Authors
A Mansfield;A Goodrich;N Foster;V Ernani;L Villaruz;P Forde;K Raghav;P Romesser;K Garbacz;L Cao;M Salvatore;A Roden;S Powell;A Shergill;P Munster;G Schwartz;T Grotz
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS8603); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Early Therapeutics and Rare Cancers

A Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (Alliance A022004)

Authors
R Yaeger;Q Shi;A Dueck;E Dib;S Kazmi;O Alese;S Krishnamurthi;A Nixon;A Shergill;E O'Reilly;J Meyerhardt
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS3641); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster
Year
2023
Research Committee(s)
Gastrointestinal